Seval, G. C., Delimpasi, S., Vorobyev, V. I., Quach, H., Špička, I., Radocha, J., Koh, Y., Robak, T., Fuente, F. D. A. D. L., García, E. G., Aytan, P., Mangiacavalli, S., Zamagni, E., Polinkovsky, M., Duggan, M., Grams, J., Manasanch, E., Mateos, M., Trudel, S., Dimopoulos, M. A. (2026). PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7566